Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyHealth Net Ravicti Coverage Update Prior Auth | Op…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy N/A

    Clinical Policy: Glycerol Phenylbutyrate (Ravicti)

    Customize your policy alerts

    Sign up for all Health Net policy alerts

    Know when Health Net releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs medical necessity criteria, prior authorization, and continuation requirements for glycerol phenylbutyrate (Ravicti) for treatment of urea cycle disorders across Health Net lines of business (Commercial, HIM, Medicaid). It specifies diagnostic confirmation, prescriber experience, stepwise redirection to alternatives, dosing limits, and approval durations.

    Policy Summary
    PayerHealth Net
    PolicyGlycerol Phenylbutyrate (Ravicti) — Clinical Policy
    Policy CodePolicy N/A
    Change TypeMaterial revision — approval duration and stepwise redirection added
    Effective Date05.01.16
    Next Review DateN/A
    Key ActionObtain prior authorization with diagnostic confirmation of UCD and documentation that stepwise redirection to generic sodium phenylbutyrate (then Pheburane if needed) and dose limits (≤17.5 mL/day) are met.
    SourceLink
    POLICY UPDATE CHANGES

    Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.

    Added stepwise redirection requiring use of generic sodium phenylbutyrate first, then Pheburane if intolerance or contraindication, for continuation of therapy and requests.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    17.5 mL/day
    Maximum Ravicti daily dose
    12 monthsCommercial approval
    6–12 monthsMedicaid/HIM approval
    UCDIndication
    NotedMedicaid precedence
    CenteneProprietary

    Coverage Criteria for Ravicti (glycerol phenylbutyrate)

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval for Ravicti: 1) Diagnosis of a UCD caused by one or more of the following, confirmed by enzymatic, biochemical, or genetic analysis: Carbamyl phosphate synthetase 1 (CPS1) deficiency; Ornithine transcarbamylase (OTC) deficiency; Argininosuccinate synthetase (AS) deficiency (classic citrullinemia, type I); Argininosuccinate lyase (ASL) deficiency (argininosuccinic aciduria); or Arginase deficiency.
    Prescriber requirement: 2) Prescribed by or in consultation with a physician experienced in treating metabolic disorders.
    Stepwise redirection for CPS1/OTC/AS: 3) For UCD caused by CPS1, OTC, or AS deficiency, BOTH: a) Member must use generic sodium phenylbutyrate unless contraindicated or clinically significant adverse events are experienced; and b) If member has intolerance or contraindication to generic sodium phenylbutyrate, member must use Pheburane unless contraindicated or clinically significant adverse effects occur.
    Dose limitation: 4) Total daily dose does not exceed 17.5 mL (19 g) per day.<= 17.5 mL/day

    inv-02: Continuation Therapy

    Covered for continuation when ALL of the following are met:

    Eligibility for continuation: 1) Member is currently receiving Ravicti via the benefit or has previously met initial approval criteria.
    Stepwise redirection for CPS1/OTC/AS: 2) For UCD caused by CPS1, OTC, or AS deficiency, BOTH: a) Member must use generic sodium phenylbutyrate unless contraindicated or clinically significant adverse events are experienced; and b) If member has intolerance or contraindication to generic sodium phenylbutyrate, member must use Pheburane unless contraindicated or clinically significant adverse effects occur.
    Clinical response: 3) Member is responding positively to therapy.
    Dose limitation for increases: 4) If the request is for a dose increase, the new total daily dose does not exceed 17.5 mL (19 g) per day.<= 17.5 mL/day

    Ravicti (glycerol phenylbutyrate) is indicated for the chronic management of urea cycle disorders (UCDs) but has specific limitations. The medication's safety and efficacy have not been established for N‑acetylglutamate synthase (NAGS) deficiency, and therefore use for NAGS deficiency is not supported by this policy. Additionally, Ravicti is not indicated for the treatment of acute hyperammonemia because acute episodes require more rapidly acting interventions to reduce plasma ammonia levels.

    Requests for uses that are non‑FDA approved and not addressed in this policy will be denied unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (e.g., CP.CPA.09 for Commercial, HIM.PA.154 for marketplace, CP.PMN.53 for Medicaid) or evidence of coverage documents.

    Coverage determinations described in this clinical policy are intended to assist in adjudicating benefits but are subject to the member's plan terms. All approvals, denials, and administration of benefits remain conditional on the Health Plan's applicable terms, conditions, exclusions, and limitations (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance), as well as state and federal requirements and Health Plan administrative policies.

    This clinical policy does not constitute medical advice or a guarantee of payment. Providers are expected to exercise independent clinical judgment in treating members and are responsible for medical decisions and documentation supporting requested services.

    Explicit non‑coverage under this chronic management policy includes requests to treat acute hyperammonemia with Ravicti — such use is not authorized because more rapidly acting therapies are required. The policy also states that Ravicti's use for NAGS deficiency is not supported due to lack of established safety and efficacy and therefore is excluded from coverage.

    In addition, non‑FDA indications that are not specifically addressed by this policy will be denied unless sufficient supporting documentation is provided per the applicable off‑label use policies or evidence of coverage provisions.

    Dosage and Coding Information

    inv-06: Maximum daily dose
    Maximum daily dose17.5 mL/day (maximum total daily Ravicti dose)
    Equivalent massApproximately 19 g/day (per policy statistics)
    Dosing schedule noteTotal daily dosage given in 3 equally divided doses; round to nearest 0.5 mL (age ≥2 years) or 0.1 mL (age <2 years)

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization required. Provider must confirm the diagnosis of a urea cycle disorder (UCD) with enzymatic, biochemical, or genetic analysis and document specialist prescribing or consultation (physician experienced in metabolic disorders). Submit chart notes, lab results, or other clinical information supporting that the member meets ALL approval criteria.

    • Confirm UCD diagnosis by enzymatic, biochemical, or genetic testing.
    • Prescribed by or in consultation with a physician experienced in treating metabolic disorders.
    • Include chart notes and relevant lab results with the prior authorization request.
    Step Therapy

    Step Therapy / Redirection Required

    Stepwise redirection to alternatives is required. For initial and continued therapy requests for members with UCD caused by CPS1, OTC, or AS deficiencies, require trial of generic sodium phenylbutyrate first. If the member has intolerance or a contraindication to generic sodium phenylbutyrate, the member must use Pheburane unless Pheburane is contraindicated or causes clinically significant adverse effects. Dose limits apply (does not exceed 17.5 mL [19 g] per day).

    Background on Urea Cycle Disorders and Ravicti

    Urea cycle disorders (UCDs) are inherited enzyme deficiencies that impair the conversion of nitrogen to urea, resulting in accumulation of ammonia and risk of hyperammonemia. Common enzyme defects include carbamyl phosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase, and N‑acetylglutamate synthase (NAGS).

    Ravicti (glycerol phenylbutyrate) is a nitrogen‑binding agent approved for the chronic management of UCDs in patients who cannot be managed by dietary protein restriction and amino acid supplementation alone. It is intended to be used with dietary protein restriction and, when appropriate, essential amino acids or arginine/citrulline supplementation. Ravicti is not indicated for the acute management of hyperammonemia and its safety/efficacy for NAGS deficiency has not been established, which is why the policy excludes use in those settings.

    Definitions and Indication Notes

    inv-16: UCD definition
    DefinitionUrea cycle disorders (UCDs) are caused by inherited deficiencies of urea-cycle enzymes that impair conversion of nitrogen to urea.
    Examples of enzyme deficienciesIncludes carbamyl phosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), argininosuccinate synthetase (AS), N-acetylglutamate synthase (NAGS), and arginase deficiencies.
    Clinical consequenceEnzyme defects can lead to hyperammonemia due to impaired nitrogen disposal.
    inv-17: Ravicti indication/limitations
    IndicationRavicti (glycerol phenylbutyrate) is indicated for chronic management of patients with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
    Adjunctive use
    Policy Summary
    PayerHealth Net
    PolicyGlycerol Phenylbutyrate (Ravicti) — Clinical Policy
    Policy CodePolicy N/A
    Change TypeMaterial revision — approval duration and stepwise redirection added
    Effective Date05.01.16
    Next Review DateN/A
    Key ActionObtain prior authorization with diagnostic confirmation of UCD and documentation that stepwise redirection to generic sodium phenylbutyrate (then Pheburane if needed) and dose limits (≤17.5 mL/day) are met.
    SourceLink
    On This Page
    Coverage Criteria for Ravicti (glycerol phenylbutyrate)Dosage and Coding InformationPrior Authorization, Documentation, and Provider RequirementsBackground on Urea Cycle Disorders and RavictiDefinitions and Indication Notes

    Approval durations differ by line of business.

    • Initial therapy: member must use generic sodium phenylbutyrate unless contraindicated or clinically significant adverse events occur.
    • If intolerance/contraindication to generic sodium phenylbutyrate, member must use Pheburane unless also contraindicated or causes significant adverse effects.
    • Continuation therapy: same stepwise redirection applies for continuation or dose increase requests.
    • Dose limit: ≤ 17.5 mL (19 g) per day.
    Denial Risk

    Non‑FDA Indications / Off‑Label Use

    Non‑FDA (off‑label) indications are not covered by this policy unless sufficient supporting documentation of efficacy and safety is provided per the applicable off‑label use policies or evidence of coverage documents. Providers should reference and comply with the plan’s off‑label use rules.

    • Non‑FDA indications denied unless documentation meets off‑label policy: CP.CPA.09 (commercial), HIM.PA.154 (Health Insurance Marketplace), CP.PMN.53 (Medicaid) as applicable.
    • Provide evidence of efficacy and safety or reference applicable evidence of coverage documents when requesting coverage for off‑label use.
    Documentation Required

    Documentation and Claims Requirements

    Documentation and claims: providers submitting requests or claims agree to be bound by the terms of this clinical policy and must ensure documentation aligns with plan coverage documents, state and federal requirements, and Health Plan administrative policies. Coverage remains subject to all plan terms, conditions, exclusions, and limitations.

    • Coverage decisions subject to evidence of coverage, certificate of coverage, policy, contract, and applicable laws and regulations.
    • Providers are responsible for maintaining documentation supporting medical necessity and for compliance with plan and regulatory requirements when submitting claims.
    Must be used with dietary protein restriction and, when needed, dietary supplements such as essential amino acids, arginine, or citrulline.
    LimitationsNot indicated for treatment of acute hyperammonemia; safety and efficacy for NAGS deficiency have not been established.
    inv-18: Clinical policy definition
    PurposeThis clinical policy was developed by licensed health care professionals to assist Health Plan coverage decisions based on current standards of medical practice and available evidence.
    Scope and useThe policy is intended to guide coverage determinations and is not a contract, guarantee of payment, or a directive for clinical practice; providers retain independent medical judgment and responsibility.
    Administrative provisoCoverage decisions are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable laws and regulations.